Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose immunosuppression with thiotepa and cyclophosphamide followed by autologous stem cell transplantation in multiple sclerosis
2007-000586-38Phase 2Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jan 2008
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, cyclophosphamide and filgrastim in multiple sclerosis (MS), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Safety and feasibility of high-dose immunosuppression followed by autologous stem cell transplantation. Started Jan 2008; status: terminated.
02
Drugs
thiotepacyclophosphamidefilgrastim
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2007-000586-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000586-38.